Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by daphnoretin from Thymelaea hirsuta root

Phytotherapy Research

Volumn 12, Issue 4, 1998, Pages 282-284

  Abou Karam, Mohamed ^a,b   El Shaer, Nagwa S ^b   Shier, W Thomas ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Cultured mammalian cells; Cytotoxicity; Daphnoretin; Thymelaea hirsuta (L.) Endl.; Thymelaeaceae; Tyrosine kinase inhibition

Indexed keywords

CYTOTOXIC AGENT; DAPHNORETIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; THYMELAEA HIRSUTA EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE NEU; PLANT ROOT; SQUAMOUS CELL CARCINOMA;

THYMELAEA HIRSUTA;

EID: 0031874399     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1573(199806)12:4<282::AID-PTR225>3.0.CO;2-X     Document Type: Article

References (17)

1. Abbas, H. K., Shier, W. T., and Mirocha, C. J. (1984). Sensitivity of cultured human and mouse fibroblasts to trichothecenes. J. Assoc. Off. Anal. Chem. 67, 607-610.
2. Campisi, J., Morreo, G., and Pardee, A. B. (1984). Kinetics of G1 transit following brief starvation for serum factors. Exp. Cell Res. 152, 459-466.
3. Cordell, G. A. (1984). Studies in the thymelaeaceae I. NMR spectral assignments of daphnoretin. J. Nat. Prod. 47, 84-88.
4. Druker, B. J., Mamon, H. J., and Roberts, T. M. (1989). Oncogenes, growth factors and signal transduction. N. Engl. J. Med. 321, 1383-1391.
5. Gazit, A., Yaish, P., Gilon, C., and Levitzki, A. (1989). Tyrphostins: synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 32, 2344-2352.
6. Gibbs, J. B., Oliff, A., and Kohl, N. E. (1994). Farnesyltransferase inhibitors: ras research yields a potential cancer chemotherapeutic. Cell, 77 175-178.
7. Hall, I. H., Tagahara, K., and Lee, K. H. (1982). Antitumor agents LIII: The effects of daphnoretin on nucleic acid and protein synthesis of Ehrlich ascites tumor cells. J. Pharm. Sci. 71, 741-744.
8. Handa, S. S., Kinghorn, A. D., Cordell, G. A., and Farnsworth, N. R. (1983). Plant anticancer agents XXVI. Constituents of Peddiea fischeri. J. Nat. Prod. 46, 248-250.
9. Kim, M., Wheeler, B., and Perry, S. (1978). Quantitative description of cell cycle kinetics under chemotherapy utilizing cytometry. Cell Tissue Kinet. 11, 497-512.
10. Levitzki, A., and Gazit, A. (1995). Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782-1788.
11. Liou, Y. F., Hall, I. H., and Lee, K. H. (1982). Antitumor agents LIV: The effects of daphnoretin on in vitro protein synthesis of Ehrlich ascites carcinoma cells and other tissues. J. Pharm. Sci. 71, 745-749.
12. Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signalregulated kinase activation. Cell 80, 179-185.
13. Panayotou, G., Hsuan, J. J., and Waterfield, M. D. (1990). Ligand- and antibody- affinity purification of the epidermal growth factor receptor. In, Receptor Purification, Vol. 1, ed. by G. Litwack, pp. 289-302, The Humana Press, Clifton, NJ.
14. Rizk, A. M., and Rimpler, H. (1972). Isolation of daphnoretin and beta-sitosterol-beta-D-glucoside from Thymelaea hirsuta. Phytochemistry 11, 473-475.
15. Shier, W. T. (1983). An undergraduate experiment to demonstrate the use of cytotoxic drugs in cancer chemotherapy. Am. J. Pharm. Ed. 47, 216-220.
16. Torrance, S. J., Hoffmann, J. J., and Cote, J. R. (1979). Wikstromol, antitumor lignan from Wikstroemia foetida var. oahuensis Gray and Wikstroemia uva-ursi Gray (Thymelaeaceae). J. Pharm. Sci. 68, 664-665.
17. Williams, M., and Cassady, J. M. (1976). Potential antitumor agents: A cytotoxic cardenolide from Coronilla varia L. J. Pharm. Sci. 65, 912-914.